A Clinical Study to Explore the Efficacy and Safety of Hyperbaric Oxygen in the Neoadjuvant Treatment of Hormone Receptor Positive Breast Cancer Patients
The goal of this study is to explore the efficacy and safety of hyperbaric oxygen in the neoadjuvant treatment of hormone receptor positive breast cancer patients
Breast Cancers
DEVICE: Hyperbaric oxygen treatment
RCB 0/1 rate, After completion of standard cycle of neoadjuvant therapy (through study completion, an average of half a year)
pCR rate after hyperbaric oxygen combined with neoadjuvant therapy in breast cancer patients, After completion of standard cycle of neoadjuvant therapy (through study completion, an average of half a year)|The Miller and payne classification, After completion of standard cycle of neoadjuvant therapy (through study completion, an average of half a year)|RECIST criteria, After completion of the first cycle of adjuvant therapy, After completion of standard cycle of neoadjuvant therapy (through study completion, an average of half a year)|Life quality (EORTC QLQ C-30„ÄÅEORTC QLQ BR-23 questionnaire), At the time of patient enrolment, Each cycle of chemotherapy (8 cycle, each cycle is 3 weeks) , Day before surgery, 3 months after surgery|Side effects of hyperbaric oxygen therapy, during the hyperbaric oxygen therapy (up to half a year)|Number of participants with treatment-related adverse events as assessed by CTCAE v5.0, through study completion ( an average of half a year)|the Tumor immune microenvironment of the Hyperbaric Oxygen Therapy and neoadjuvant therapy, the time when the patient enrollment, at the end of the first cycle of neoadjuvant therapy (at about the first month) , surgery
The goal of this study is to explore the efficacy and safety of hyperbaric oxygen in the neoadjuvant treatment of hormone receptor positive breast cancer patients